Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $43.60.

INO has been the subject of a number of research reports. Oppenheimer dropped their price target on Inovio Pharmaceuticals from $40.00 to $33.00 and set an "outperform" rating for the company in a research note on Monday, August 12th. Royal Bank of Canada cut their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a "sector perform" rating on the stock in a research note on Friday.

Inovio Pharmaceuticals Trading Down 10.6 %

NASDAQ:INO traded down $0.50 on Friday, hitting $4.27. The company had a trading volume of 670,926 shares, compared to its average volume of 300,272. The firm has a 50 day moving average of $5.75 and a two-hundred day moving average of $8.14. The stock has a market capitalization of $110.72 million, a price-to-earnings ratio of -1.18 and a beta of 0.83. Inovio Pharmaceuticals has a 52 week low of $4.20 and a 52 week high of $14.75.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its stake in Inovio Pharmaceuticals by 177.0% during the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 3,630 shares in the last quarter. MetLife Investment Management LLC boosted its position in shares of Inovio Pharmaceuticals by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company's stock worth $88,000 after purchasing an additional 8,546 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Inovio Pharmaceuticals in the 2nd quarter valued at about $82,000. Signature Estate & Investment Advisors LLC bought a new stake in Inovio Pharmaceuticals in the 2nd quarter valued at about $88,000. Finally, American Century Companies Inc. raised its stake in Inovio Pharmaceuticals by 62.2% during the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company's stock worth $255,000 after buying an additional 12,100 shares during the period. Institutional investors own 26.79% of the company's stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.